The evidence leans constructive9 supporting, 1 against, 1 worth knowing
Supporting
trading 86% above its 200-day average
sitting at 99% of its 52-week range, with little overhead supply from trapped buyers
up 94% over twelve months
matches stretched far above trend, which has beaten the market by +0.82 points over 20 sessions across 27,715 past signals
3 of the scans it matches have a positive measured record
7 independent kinds of evidence agree today, which is uncommon
revenue grew 59% year on year in the quarter ending 2026-06-30
net margin has widened from 10.0% to 21.7% across four quarters
priced at 0× earnings against an industry median of 44× — 100% below its peers
Against
1 of the scans it matches has historically underperformed the market
Worth knowing
RSI at 87 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 439, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
17 of 47 matched on 2026-08-21
SHILPAMED matches 17 of the 47 scans today, across 7 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 2024-09-06
0×
median 0×
0×
now 0×
SHILPAMED trades at 0× trailing earnings, below its median of 0× over this window — 29% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Dividend filings were typically -0.09pt vs the market over the next 5 sessions (n=634) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 59% against the same quarter a year earlier
profit rose 617% year on year
revenue rose in 3 of the last 4 quarters
Going against it
net margin narrowed from 24.7% to 21.7%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
466
92
101
5.16
21.7%
Q4 FY26
2026-03-31 · consolidated
437
120
108
5.51
24.7%
Q3 FY26
2025-12-31 · consolidated
410
61
45
2.36
10.9%
Q3 FY25
2024-12-31 · consolidated
319
41
32
3.25
10.0%
Q2 FY25
2024-09-30 · consolidated
344
37
18
1.83
5.2%
Q1 FY25
2024-06-30 · consolidated
293
32
14
1.46
4.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+25.3%
Versus 200-day average+85.7%
Below 52-week high-0.9%
Above 52-week low+205.2%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)86.5
Higher closes in last 52 of 5
Six-month return+139.87%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.52%
Volume versus 20-day0.2x
Median daily turnoverRs 78.7 cr
Peers
Healthcare · 67 classified companies
SHILPAMED trades at 0.0× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 100%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-18
5
The market's strongest stocks, Beating the market for 6 months, Stretched far above trend, Long tail above — rejected higher, Above the 200-day EMA